The role of dipeptidyl peptidase-4 inhibitors

BMJ ◽  
2012 ◽  
Vol 344 (mar12 1) ◽  
pp. e1213-e1213 ◽  
Author(s):  
D. Lasserson ◽  
J. Mant
Keyword(s):  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors

2017 ◽  
Vol 126 (05) ◽  
pp. 268-276 ◽  
Author(s):  
Fernando Gómez-Peralta ◽  
Cristina Abreu ◽  
Gustavo Mora-Navarro ◽  
Pilar López-Morandeira ◽  
Esteban Pérez-Gutierrez ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Basal Insulin ◽  
Insulin Analogue ◽  
Dipeptidyl Peptidase ◽  
Premixed Insulin ◽  
Dipeptidyl Peptidase 4 ◽  
Metformin Group ◽  
Dipeptidyl Peptidase 4 Inhibitors

Abstract Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice. Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients’ medical charts. Results Switching to a basal insulin plus OADs decreased HbA1c (−1.0%, p<0.001), fasting (−38.1 mg/dl, p<0.001) and postprandial glycemia (−36.1 mg/dl, p<0.001), with reduced body weight (−1.1 kg, p<0.001) and hypoglycemic episodes (−17.5%, p<0.001). 68 (36.6%) patients received a basal insulin plus DPP-4 inhibitor±metformin and 74 (39.8%) plus metformin only. The DPP-4 inhibitor±metformin group showed a greater HbA1c reduction than the metformin group (1.3±1.4% vs. 0.9±1.0%, p=0.022), with no significant differences between groups in hypoglycemic episodes. Conclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients’ glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.

Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors

2016 ◽  
Vol 17 (10) ◽  
pp. 896-901 ◽  
Author(s):  
Maria Rosaria Rizzo ◽  
Michelangela Barbieri ◽  
Ilaria Fava ◽  
Manuela Desiderio ◽  
Carla Coppola ◽  
...  
Keyword(s):  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Therapeutic Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19

2020 ◽  
pp. 1-4
Author(s):  
Nasser Mikhail ◽  
◽  
Soma Wali ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Studies ◽  
Clinical Status ◽  
Dipeptidyl Peptidase ◽  
Therapeutic Role ◽  
Dipeptidyl Peptidase 4 ◽  
Beneficial Effects ◽  
Dipeptidyl Peptidase 4 Inhibitors

Background: Limited retrospective data suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin may decrease mortality in patients with type 2 diabetes hospitalized with coronavirus disease 2019 (COVID-19). Objective: To review the strength of evidence that supports possible therapeutic role of DPP-4 inhibitors in COVID-19. Methods: PUBMED search until October 10, 2020. Search terms included COVID-19, DPP-4 inhibitors, sitagliptin, CD26, mortality, diabetes. Retrospective studies, pertinent animal investigations and pre-print studies are reviewed. Results: Three retrospective studies have shown that use of DPP-4 inhibitors was associated with significant mortality reduction of approximately 56- 87% in patients with diabetes admitted with COVID-19. In addition, in one of these studies, the use of sitagliptin before hospitalization was associated with greater number of hospital discharges, improvement of clinical status, reduced risk of transfer to intensive care unit (ICU) and need for mechanical ventilation compared with patients who were not receiving sitagliptin. Moreover, there was significant decrease in some pro-inflammatory markers in the sitagliptin group. A small retrospective study of 9 patients who were taking a DPP-4 inhibitor prior to admission did not find any significant effect of DPP-4 inhibitors on mortality and clinical outcomes after hospitalization. Results of another small study suggested increase susceptibility to COVID-19, but not to its severity, in patients taking DPP-4 inhibitors. Conclusions: Weak evidence derived from observational studies suggests possible beneficial effects of DPP-4 inhibitors use in patients with type 2 diabetes and COVID-19. Randomized trials are urgently needed to clarify the efficacy and safety of DPP-4 inhibitors in patients with COVID-19 with and without type 2 diabetes

scholarly journals Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Chun-Fan Chen ◽  
Chian-Hsu Chien ◽  
Yi-Ping Yang ◽  
Shih-Jie Chou ◽  
Mong-Lien Wang ◽  
...  
Keyword(s):  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation

2016 ◽  
Vol 207 ◽  
pp. 46-47 ◽  
Author(s):  
Xiaowei Zhang ◽  
Zhiwei Zhang ◽  
Mingzhen Li ◽  
Guangping Li ◽  
Tong Liu
Keyword(s):  
Atrial Fibrillation ◽  
Potential Role ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2

2020 ◽  
Vol 4 (6) ◽  
pp. 334-339
Author(s):  
T.Yu. Demidova ◽  
◽  
A.A. Kozhevnikov ◽  
Keyword(s):  
Combined Treatment ◽  
Diabetes Type 2 ◽  
Dipeptidyl Peptidase ◽  
Diabetes Type ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucose Lowering Therapy

Diabetes is a progressive disease that manifests itself in hyperglycemia and is associated with macro- and microvascular complications. Stepwise approach to glucose-lowering therapy is now often questioned for two main reasons. First, the decision on intensifying the treatment requires the decompensation of carbohydrate metabolism. Second, this conception does not always meet the criteria of pathophysiological treatment, in particular, in patients who are newly diagnosed with diabetes type 2 and recommended with metformin monotherapy. The combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors is a well-known strategy that effectively controls blood glucose level and preserves beta cell functions. VERIFY study has demonstrated that after a 5-year follow-up, median time to type 2 diabetes decompensation is 36.1 months in metformin group and 61.9 months in early combined treatment group (metformin plus vildagliptin) (p<0.0001). These findings can account for paradigm shift in treatment prescription for newly diagnosed type 2 diabetes in patients with HbA1c less than 1,0% of the target level.KEYWORDS: diabetes, glucose-lowering therapy, control of glycemia, combined treatment.FOR CITATION: Demidova T.Yu., Kozhevnikov A.A. Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2. Russian Medical Inquiry. 2020;4(6):334–339. DOI: 10.32364/2587-6821-2020-4-6-334-339.

Sign in / Sign up

Export Citation Format

Share Document